Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 + KEYTRUDA in Patients with SMARCA4-Mutated Cancers July 17, 2024
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for novel ADC July 17, 2024
Nona Biosciences Enters into Collaboration Agreement with Alaya.bio to Advance CAR-T Cell Therapy July 17, 2024
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 anti-VISTA Checkpoint Inhibitor July 17, 2024
ReEngage Therapeutics Announces Research Agreement to Accelerate Development of ACSS2 Inhibitors as Cancer Therapies July 17, 2024
Eisai and BMS end global strategic collaboration for the co-development and co-commercialization of farletuzumab ecteribulin; now all rights with Eisai July 9, 2024
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor July 9, 2024
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced NET based on positive CABINET Ph 3 trial July 9, 2024
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat for the Treatment of Metastatic CRPC July 9, 2024
Ubix Therapeutics and Yuhan Announce Exclusive License Agreement for UBX-103 for Treatment of Metastatic CRPC July 9, 2024
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 July 9, 2024
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies July 1, 2024
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage ADC Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers June 25, 2024
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial June 25, 2024
Lead Selection for MDG2021 Announced, Expanding TCR-T KRAS Library Targeting Solid Tumors June 25, 2024
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib June 18, 2024
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors June 18, 2024
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial June 18, 2024
Immutep and MSD to Evaluate Efti in Combination with KEYTRUDA in Pivotal Ph 3 TACTI-004 Trial June 11, 2024
FibroGen Announces Clinical Trial Supply Agreement with Regeneron to Evaluate FG-3165 and FG-3175 in Combination with LIBTAYO in Upcoming Clinical Trials June 11, 2024
